Reducing atherothrombotic events in high-risk patients: Recent data on therapy with statins and fatty acids

Current Atherosclerosis Reports

Volumn 1, Issue 1, 1999, Pages 6-8

  Ballantyne, Christie M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Angiographic Restenosis; Atorvastatin; Fluvastatin; Major Adverse Coronary Event; Statin Therapy

Indexed keywords

EDIBLE OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; OMEGA 3 FATTY ACID;

CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; HEART MUSCLE REVASCULARIZATION; HUMAN; REVIEW; RISK FACTOR; THROMBOSIS;

ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; DIETARY FATS, UNSATURATED; FATTY ACIDS, OMEGA-3; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL REVASCULARIZATION; RISK FACTORS; THROMBOSIS;

EID: 0033156992     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-999-0043-5     Document Type: Article

References (8)

1. Serruys PW, Foley DP, Jackson G, et al., on behalf of the FLARE study group: A randomized placebo-controlled trial of fluvastatin for preventiton of restenosis after successful coronary balloon angioplasty: final results of the Fluvastatin Angiographic Restenosis (FLARE) Trial. Eur Heart J 1999, 20:58–69. DOI: 10.1053/euhj.1998.1150
2. Weintraub WS, Boccuzzi SJ, Klein JL, et al., for the Lovastatin Restenosis Trial Study Group: Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994, 331:1331–1337. DOI: 10.1056/NEJM199411173312002
3. Bertrand ME, McFadden EP, Fruchart JC, et al., for the PREDICT Trial Investigators: Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 1997, 30:863–869. DOI: 10.1016/S0735-1097(97)00259-3
4. McCormick LS, Black DM, Waters D, et al., for the AVERT Investigators: Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with atorvastatin versus revascularization treatments (AVERT). Am J Cardiol 1997, 80:1130–1133. DOI: 10.1016/S0002-9149(97)00627-9
5. de Lorgeril M, Renaud S, Mamelle N, et al.: Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994, 343:1454–1459. DOI: 10.1016/S0140-6736(94)92580-1
6. de Lorgeril M, Salen P, Martin J-L, et al.: Effect of a Mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease: insights into the cardioprotective effect of certain nutriments. J Am Coll Cardiol 1996, 28:1103–1108. DOI: 10.1016/S0735-1097(96)00280-X
7. de Lorgeril M, Salen P, Martin J-L, et al.: Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999, 99:779–785.
8. Leaf A: Dietary prevention of coronary heart disease: the Lyon Diet Heart Study [editorial]. Circulation 1999, 99:733–735.